ZFIN ID: ZDB-FISH-150901-12164
Fish name: vhlhu2117/hu2117
Genotype: vhlhu2117/hu2117
Targeting Reagent: none
HUMAN DISEASE MODELED by vhlhu2117/hu2117
Human Disease Conditions Citations
von Hippel-Lindau disease standard conditions Martins Metelo et al., 2015
clear cell renal cell carcinoma standard conditions Noonan et al., 2016
familial erythrocytosis 2 standard conditions van Rooijen et al., 2009
GENE EXPRESSION
Gene expression in vhlhu2117/hu2117
RNA expression
Expressed Gene Structure Conditions Figures
alas2 standard conditions Table 1 from Kim et al., 2020
baxa control Fig. 1 from Essers et al., 2015
gamma ray Fig. 1 from Essers et al., 2015
bbc3 control Fig. 1 from Essers et al., 2015
gamma ray Fig. 1 from Essers et al., 2015
birc2 control Fig. 4 from Essers et al., 2015
gamma ray Fig. 4 from Essers et al., 2015
birc5a control Fig. 4 from Essers et al., 2015
gamma ray Fig. 4 from Essers et al., 2015
cdkn1a control Fig. 1 from Essers et al., 2015
gamma ray Fig. 1 from Essers et al., 2015
cflara control Fig. 4 from Essers et al., 2015
gamma ray Fig. 4 from Essers et al., 2015
cxcr4a standard conditions Fig. 2 from van Rooijen et al., 2018
egln3 standard conditions Table 1 from Kim et al., 2020
gata1a standard conditions Table 1 from Kim et al., 2020
ldha standard conditions Fig. 5 with image from Marchi et al., 2020
Fig. S9 with image from van der Velden et al., 2011
chemical treatment by environment: betamethasone dipropionate Fig. 5 with image from Marchi et al., 2020
mknk2b standard conditions Table 1 from Kim et al., 2020
ndufa4b standard conditions Fig. S9 with image from van der Velden et al., 2011
vegfaa standard conditions Table 1 from Kim et al., 2020
PHENOTYPE
Phenotype in vhlhu2117/hu2117
Phenotype Conditions Figures
angiogenesis increased process quality, abnormal standard conditions Fig. 4,  Fig. 5 from Martins Metelo et al., 2015
capillary loop nephron dilated, abnormal standard conditions Fig. 2 from van Rooijen et al., 2018
capillary loop nephron cxcr4a expression increased amount, abnormal standard conditions Fig. 2 from van Rooijen et al., 2018
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest decreased process quality, abnormal gamma ray Fig. 4 from Essers et al., 2015
erythrocyte differentiation increased process quality, abnormal standard conditions Fig. 4,  Fig. 5 from Martins Metelo et al., 2015
head ldha expression increased amount, abnormal standard conditions Fig. 5 with image from Marchi et al., 2020
head ldha expression increased amount, abnormal chemical treatment by environment: betamethasone dipropionate Fig. 5 with image from Marchi et al., 2020
heart contraction process quality, abnormal control Fig. 6 from Martins Metelo et al., 2015
intestinal epithelium shape, normal standard conditions Fig. 6 with image from van der Velden et al., 2011
liver color, normal standard conditions Fig. 6 with image from van der Velden et al., 2011
liver ldha expression increased amount, abnormal standard conditions Fig. 5 with image from Marchi et al., 2020
liver ldha expression increased amount, abnormal chemical treatment by environment: betamethasone dipropionate Fig. 5 with image from Marchi et al., 2020
pronephric capsular space increased width, abnormal standard conditions Fig. 2 from van Rooijen et al., 2018
pronephric glomerulus increased size, abnormal standard conditions Fig. 2 from van Rooijen et al., 2018
pronephric podocyte cxcr4a expression increased amount, abnormal standard conditions Fig. 2 from van Rooijen et al., 2018
pronephric proximal convoluted tubule apical-basal polarity, abnormal standard conditions Fig. 1 with image from Noonan et al., 2016
pronephric proximal convoluted tubule diameter, ameliorated chemical treatment by environment: EC 1.14.11.29 (hypoxia-inducible factor-proline dioxygenase) inhibitor Fig. 7 with image from Noonan et al., 2016
pronephric proximal convoluted tubule increased diameter, abnormal standard conditions Fig. 1 with image,  Fig. 2 with image,  Fig. 7 with image from Noonan et al., 2016
pronephric proximal convoluted tubule cell botryoidal, abnormal standard conditions Fig. 1 from van Rooijen et al., 2018
pronephric proximal convoluted tubule ciliated epithelial cell disorganized, abnormal standard conditions Fig. 2 with image,  Fig. 7 with image from Noonan et al., 2016
pronephric proximal convoluted tubule ciliated epithelial cell organization quality, ameliorated chemical treatment by environment: EC 1.14.11.29 (hypoxia-inducible factor-proline dioxygenase) inhibitor Fig. 7 with image from Noonan et al., 2016
pronephric proximal convoluted tubule cytoplasm has extra parts of type pronephric proximal convoluted tubule vesicle, abnormal standard conditions Fig. 3 from van Rooijen et al., 2018
pronephric proximal convoluted tubule cytoplasmic vesicle amount, ameliorated chemical treatment by environment: EC 1.14.11.29 (hypoxia-inducible factor-proline dioxygenase) inhibitor Fig. 7 with image from Noonan et al., 2016
pronephric proximal convoluted tubule cytoplasmic vesicle increased amount, abnormal standard conditions Fig. 1 with image,  Fig. 7 with image from Noonan et al., 2016
pronephric proximal convoluted tubule epithelial cell decreased amount, abnormal standard conditions Fig. 1 with image,  Fig. 7 with image from Noonan et al., 2016
pronephric proximal convoluted tubule vesicle increased variability of size, abnormal standard conditions Fig. 3 from van Rooijen et al., 2018
pronephric proximal straight tubule apical-basal polarity, abnormal standard conditions Fig. 1 with image from Noonan et al., 2016
pronephric proximal straight tubule diameter, ameliorated chemical treatment by environment: EC 1.14.11.29 (hypoxia-inducible factor-proline dioxygenase) inhibitor Fig. 7 with image from Noonan et al., 2016
pronephric proximal straight tubule increased diameter, abnormal standard conditions Fig. 1 with image,  Fig. 2 with image,  Fig. 7 with image from Noonan et al., 2016
pronephric proximal straight tubule cell botryoidal, abnormal standard conditions Fig. 1 from van Rooijen et al., 2018
pronephric proximal straight tubule ciliated epithelial cell disorganized, abnormal standard conditions Fig. 2 with image,  Fig. 7 with image from Noonan et al., 2016
pronephric proximal straight tubule ciliated epithelial cell organization quality, ameliorated chemical treatment by environment: EC 1.14.11.29 (hypoxia-inducible factor-proline dioxygenase) inhibitor Fig. 7 with image from Noonan et al., 2016
pronephric proximal straight tubule cytoplasm has normal numbers of parts of type pronephric proximal straight tubule vesicle, normal standard conditions Fig. 3 from van Rooijen et al., 2018
pronephric proximal straight tubule cytoplasmic vesicle amount, ameliorated chemical treatment by environment: EC 1.14.11.29 (hypoxia-inducible factor-proline dioxygenase) inhibitor Fig. 7 with image from Noonan et al., 2016
pronephric proximal straight tubule cytoplasmic vesicle increased amount, abnormal standard conditions Fig. 1 with image,  Fig. 7 with image from Noonan et al., 2016
pronephric proximal straight tubule epithelial cell decreased amount, abnormal standard conditions Fig. 1 with image,  Fig. 7 with image from Noonan et al., 2016
pronephros development decreased process quality, abnormal standard conditions Fig. 1,  Fig. 2,  Fig. 3 from van Rooijen et al., 2018
proximal convoluted tubule cell population proliferation occurrence, normal standard conditions Fig. 2 from van Rooijen et al., 2018
proximal straight tubule cell population proliferation occurrence, normal standard conditions Fig. 2 from van Rooijen et al., 2018
regulation of cell cycle decreased process quality, abnormal gamma ray Fig. 4 from Essers et al., 2015
whole organism Ab2-mdm2 labeling decreased amount, abnormal gamma ray Fig. 3 from Essers et al., 2015
whole organism Ab2-mdm2 labeling decreased amount, abnormal control Fig. 3 from Essers et al., 2015
whole organism decreased life span, abnormal control Fig. 6 from Martins Metelo et al., 2015
whole organism decreased life span, ameliorated chemical treatment: antimycin A Fig. 4 from Jain et al., 2016
whole organism mknk2b expression increased amount, abnormal standard conditions Table 1 from Kim et al., 2020
whole organism alas2 expression increased amount, abnormal standard conditions Table 1 from Kim et al., 2020
whole organism Ab14-tp53 labeling increased amount, abnormal control Fig. 1 from Essers et al., 2015
whole organism gata1a expression increased amount, abnormal standard conditions Table 1 from Kim et al., 2020
whole organism bbc3 expression increased amount, abnormal gamma ray Fig. 1 from Essers et al., 2015
whole organism baxa expression increased amount, abnormal gamma ray Fig. 1 from Essers et al., 2015
whole organism Ab14-tp53 labeling increased amount, abnormal gamma ray Fig. 1 from Essers et al., 2015
whole organism egln3 expression increased amount, abnormal standard conditions Table 1 from Kim et al., 2020
whole organism cdkn1a expression increased amount, abnormal gamma ray Fig. 1 from Essers et al., 2015
whole organism vegfaa expression increased amount, abnormal standard conditions Table 1 from Kim et al., 2020
whole organism birc5a expression increased amount, abnormal control Fig. 4 from Essers et al., 2015

CITATIONS  (15)

Your Input Welcome
We welcome your input and comments. Please use this form to recommend updates to the information in ZFIN. We appreciate as much detail as possible and references as appropriate. We will review your comments promptly.
Please check the highlighted fields and try again.
Thank you for submitting comments. Your input has been emailed to ZFIN curators who may contact you if additional information is required.
Oops. Something went wrong. Please try again later.